Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06457477
NA

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Sponsor: Beijing 302 Hospital

View on ClinicalTrials.gov

Summary

This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.

Official title: The Safety and Efficacy of Sequential Combination Therapy With PD-1 Antibody and Pegylated Interferon-α in NA-supressed Chronic Hepatitis B Patients

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2024-06-15

Completion Date

2025-12-15

Last Updated

2024-06-20

Healthy Volunteers

No

Interventions

DRUG

Sintilimab

100mg/10ml/1bottle

DRUG

NAs

tablets

DRUG

Peg-IFNα-2b

180ug/0.5ml/1bottle

Locations (1)

the Fifth Medical Center, Chinese PLA General Hospital

Beijing, Beijing Municipality, China